Skip to content

View Spec Sheet

open_in_new
  1. Shop all
  2. Polyclonal

200-901-BB7

erbB-2 Antibody

Cannot supply to this region.

SKU:
200-901-BB7
Additional Names:
erbB-2 Antibody, NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu, MLN19, NEU, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein|ERBB2
Application:
ELISA, IHC, WB, IF, IP
Concentration:
1 mg/ml
Physical State:
Liquid
Species Reactivity:
Human
Storage Conditions:
-20[o]C aliquoted. Aliquot. Avoid freeze/thaw cycles., 2-8[o]C diluted. Aliquot. Avoid freeze/thaw cycles.
Supplier:
Rockland Inc
Host:
Chicken/Avian
Reactivities:
Human, Mouse, Rat
Buffer:
0.01 M Sodium Phosphate, 0.25 M Sodium Chloride
Immunogen:
Anti-erbB-2 antibody was prepared from chicken egg fractions produced by repeated immunizations with a 19 amino acid synthetic peptide near the C-terminus of human erbB-2.
Formulation:
0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2
Uniprot:
P04626
Synonyms:
c-erb B2/neu protein;CD340;HER-2;HER-2/neu;HER2;herstatin;human epidermal growth factor receptor 2;metastatic lymph node gene 19 protein;MLN 19;NEU;neuro/glioblastoma derived oncogene homolog;neuroblastoma/glioblastoma derived oncogene homolog;NGL;p185erbB2;proto-oncogene c-ErbB-2;proto-oncogene Neu;receptor tyrosine-protein kinase erbB-2;TKR1;tyrosine kinase-type cell surface receptor HER2;v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2;v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2;v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog;VSCN2
Extra Details:
The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.
Shipping Conditions:
Dry Ice